Darbepoetin Alfa Safe, Effective for Elderly Chemo Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

BOSTON-Darbepoetin alfa (Ara-nesp), the new long-lasting erythropoietic agent, is safe and effective for treatment of chemotherapy-induced anemia in older patients, Lodovico Balducci, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, told ONI at the third meeting of the International Society of Geriatric Oncology (SIOG abstract P-12).

BOSTON—Darbepoetin alfa (Ara-nesp), the new long-lasting erythropoietic agent, is safe and effective for treatment of chemotherapy-induced anemia in older patients, Lodovico Balducci, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, told ONI at the third meeting of the International Society of Geriatric Oncology (SIOG abstract P-12).

Dr. Balducci and his colleagues pooled data from three similarly designed studies. All 305 patients in the analysis received an average dose of 1.5 to 2.25 µg/kg of darbepoetin alfa or placebo every 1 or 2 weeks during 12 weeks of chemotherapy. In one analysis, 138 patients aged 65 and older were matched against 167 patients under age 65. In another, 35 patients aged 75 and older were compared with 270 patients under age 75.

In both analyses, similar results were reported for older and younger cohorts. Mean hemoglobin increases for patients receiving darbepoetin were 1.4, 1.3, 1.4, and 1.1 g/dL for patients under 65, age 65 and over, under 75, and 75 and over, respectively. At all ages, mean hemoglobin levels decreased in the placebo group.

At week 5, for the darbepoetin patients, red blood cell transfusions were required in 33%, 25%, 29%, and 30% of those under 65, age 65 and over, under 75, and 75 and over, respectively. Half or more of the patients given placebo required transfusions, with the proportion reaching 70% among those 75 and older.

By studies’ end, about 65% of patients under and over age 65 had a hemoglobin increase of 2 g/dL or more, or maintained their hemoglobin levels at 12 g/dL or higher. There were no significant differences in adverse events, which were typical of chemotherapy. 

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content